| 29 May, 08:16 pm | — | … | Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. | nse |
| 29 May, 08:15 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Outcome for Audited Financial Results And Recommendation Of Final Dividend | bse |
| 26 May, 05:00 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Compliances-Reg.24(A)-Annual Secretarial Compliance | bse |
| 23 May, 09:26 am | — | … | Settlement Agreement: Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, | nse |
| 20 May, 04:23 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 20 May, 04:23 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 20, 2026, titled "Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors". | nse |
| 19 May, 04:48 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Audited Financial Results And Recommending Dividend, If Any, On Equity Shares For The Year Ended March 31, 2026. | bse |
| 18 May, 08:56 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 18 May, 08:56 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 18, 2026, titled "Glenmark Pharmaceuticals Inc., USA Launches Vancomycin Hydrochloride for Injection USP, 500mg/vial and 1 g/vial". | nse |
| 30 Apr, 05:21 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 | bse |
| 30 Apr, 05:09 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | bse |
| 09 Apr, 08:51 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 09 Apr, 08:50 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 09, 2026, titled "Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg". | nse |
| 07 Apr, 03:13 pm | — | … | Glenmark Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. | nse |
| 01 Apr, 07:08 pm | — | … | Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Regulatory action/ inspection | nse |
| 01 Apr, 05:30 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 01, 2026, titled "Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS in the U.S., Significantly Expanding its Innovative Portfolio. RYALTRIS is Glenmark s first innovative product introduced into the U.S. market". | nse |
| 01 Apr, 05:30 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 21 Mar, 12:28 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Glenmark Pharmaceuticals Launches GLIPIQ (Semaglutide) In India. Setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at Rs. 325". | nse |
| 21 Mar, 12:15 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 21 Mar, 12:15 am | — | … | Glenmark Pharmaceuticals Launches GLIPIQⓇ (Semaglutide) In India. Setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at ₹325. | nse |
| 19 Mar, 08:37 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg". | nse |
| 19 Mar, 08:37 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 19 Mar, 08:34 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Glenmark Therapeutics Inc., USA launches Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)". | nse |
| 19 Mar, 08:32 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 16 Mar, 08:45 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 16 Mar, 08:43 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Glenmark Pharmaceuticals Inc., USA to launchPotassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials". | nse |
| 04 Mar, 08:37 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 04 Mar, 08:36 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity". | nse |
| 27 Feb, 09:21 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 27 Feb, 09:19 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 27, 2026, titled "Glenmark Pharmaceuticals Inc., USA to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials". | nse |
| 20 Feb, 05:29 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange about ESG Rating. | nse |
| 20 Feb, 05:29 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement Under Regulation 30 Of The SEBI LODR | bse |
| 04 Feb, 03:20 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange about Transcript | nse |
| 04 Feb, 03:16 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | bse |
| 02 Feb, 01:42 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange about Link of Recording | nse |
| 02 Feb, 01:38 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | bse |
| 31 Jan, 09:13 pm | — | … | Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Regulatory action/ inspection | nse |
| 30 Jan, 08:20 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange about Investor Presentation | nse |
| 30 Jan, 08:20 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation | bse |
| 30 Jan, 08:13 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release and Management Discussion & Analysis"". | nse |
| 30 Jan, 08:12 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 30 Jan, 08:07 pm | — | … | Glenmark Pharmaceuticals Limited has submitted to the Exchange, Unaudited Financial Results (Standalone and Consolidated) for the Third Quarter and Nine Monthsended 31st December, 2025. | nse |
| 19 Jan, 05:23 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31, 2025. | bse |
| 05 Jan, 04:43 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement Under Regulation 30 Of The SEBI (LODR) | bse |
| 05 Jan, 04:42 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange about ESG Rating. | nse |
| 23 Dec, 08:44 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 23 Dec, 08:42 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP,30 mg/30 mL (1 mg/mL) Multiple-Dose Vial". | nse |
| 16 Dec, 03:35 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 16 Dec, 03:34 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 16, 2025, titled "Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma". | nse |
| 11 Dec, 08:44 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |